(PharmaNewsWire.Com, January 07, 2020 ) The key factors driving the growth of this market are increasing approvals for contrast agents and rising volume of CT & MRI examinations globally.
By type, the iodinated contrast media segment is expected to account for the largest share of the market in 2019
Based on type, the contrast media market is segmented into iodinated contrast media, gadolinium-based contrast media, barium-based contrast media, and microbubble contrast media. In 2019, the iodinated contrast media segment is estimated to account for the largest share of the contrast media industry. The large share of this segment can be attributed due to its high usage in CT examinations coupled with the fact that it can be used in almost all body parts.
By modality, the X-ray/CT segment is expected to account for the largest share of the market in 2019
Based on modality, the market is segmented into X-ray/CT, MRI, and ultrasound procedures. In 2019, X-ray/CT procedures segment is expected to command the largest share of the global contrast media market. The large share of this segment can be attributed to the increasing number of CT examinations across the globe, coupled with advancements in CT imaging technologies.
North America to dominate the market in 2019
North America, Europe, Asia Pacific, and the Rest of the World (RoW) are the regions considered for geographic analysis of the global contrast media market study. North America is expected to account for the largest share of the global contrast media industry. The large share of North America is attributed to the increasing number of diagnostic imaging units and examinations, growing aging population & rising prevalence of chronic conditions in the US, significant focus & government investments in the field of medical imaging, and increasing research activities in Canada.
The prominent players in the global contrast media market include GE Healthcare (US), Bracco Imaging (Italy), Bayer (Germany), and Guerbet (France) are the major players operating in the market. Other prominent players in the market are Lantheus (US), Daiichi Sankyo (Japan), Unijules (India), J.B. Chemicals (India), Sanochemia (Austria), Taejoon Pharm (South Korea), Jodas (India), and Magnus Health (India).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
